Feed HSDT
HS

Helius Medical Technologies, Inc. HSDT NASDAQ · Financials · United States

$1.86 +1.64% +$0.03

Market cap
$106.6M
Enterprise value
$102.9M
P/E
-
Forward P/E
-
PEG
-
P/S
8.8x
P/FCF
-
EV/EBITDA
-
ROIC
-14.2%
Gross margin
95.5%
Net margin
-1,302.8%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.07
Free float
69.1%

About the company

Helius Medical Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of neurostimulation therapies for the treatment of neurological disorders. Its main product platform is the Portable Neuromodulation Stimulator (PoNS) technology, which utilizes tongue stimulation to influence brain function and the nervous system. This technology has the potential to help patients with various neurological disorders, including traumatic brain injury, multiple sclerosis, and other neurological conditions. The company focuses on conducting clinical trials and obtaining regulatory approvals for its therapeutic products. Its goal is to provide innovative and effective treatment methods to improve the quality of life for patients suffering from neurological disorders. Shares of Helius Medical Technologies, Inc. may be an interesting investment opportunity for investors following the biopharmaceutical industry and neurological medicine.

Sector

Financial Services

Industry

Asset Management

CEO

Dane Carl Andreeff

Employees

21

Headquarters

Newtown

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 97% a year over the last 3 years.
  • What to watch: It missed profit estimates 4 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy